Company Overview - Tiziana Life Sciences Ltd. (TLSA) is a biotech company focused on developing Foralumab, an anti-CD3 monoclonal antibody designed for intranasal delivery to modulate immune responses in the brain [1]. Product Development - Foralumab aims to induce regulatory T cells (Tregs) and calm immune responses, potentially offering therapeutic benefits in various neurological conditions [1].